Drug intelligence / Profile preview

atiprimod + ursodiol

Development stage: Discontinued
Lead developer: Callisto Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Atiprimod + ursodiol is an experimental combination therapy formerly investigated for the treatment of multiple myeloma. Atiprimod is an oral small molecule azaspirane that acts as a STAT3 inhibitor, blocking IL-6 and VEGF signaling pathways and inducing apoptosis by downregulating anti-apoptotic proteins such as Bcl-2, Bcl-XL, and Mcl-1. Ursodiol (ursodeoxycholic acid) was co-administered in clinical trials to mitigate potential hepatobiliary toxicity associated with high-dose atiprimod. The regimen reached Phase II clinical development under AnorMED but was ultimately discontinued.

Other names: atiprimodursodiolursodeoxycholic acidatiprimod dihydrochloride

Targets

JAK2 (Janus kinase 2)JAK3 (Janus kinase 3)

Beyond the preview

Go deeper on atiprimod + ursodiol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on atiprimod + ursodiol.

Explore the full profile